Revelation Biosciences, Inc. held a Special Meeting on March 18, 2026, where stockholders approved the issuance of common stock pursuant to Class J Common Stock Warrants to exceed the Nasdaq Exchange Cap of 20% of outstanding shares. This approval sets the warrants' expiration date to March 18, 2031, enabling potential exercises without further stockholder consent.
Key takeaways
Special Meeting held March 18, 2026, with 4,171,735 shares present (quorum >1/3 of 10,492,469 outstanding shares)
Proposal 1 approved: issuance of shares under Class J Warrants exceeding 20% Exchange Cap (For: 4,033,345; Against: 104,162; Abstain: 34,228; no broker non-votes)
Proposal 2 approved: discretionary authority to adjourn meeting (For: 4,044,322; Against: 92,422; Abstain: 34,991; no broker non-votes)
Class J Warrants issued January 26, 2026, with expiration extended to March 18, 2031 post-approval
Definitive proxy statement filed February 17, 2026